Pharmacometric evaluation of viral clearance rates based on frequent oropharyngeal sampling is a highly efficient and well-tolerated method of assessing and comparing SARS-CoV-2 antiviral therapeutics in vivo.

A model-based approach for modelling the immune control of viral dynamics is applied to quantify the effect of several SARS-CoV-2 vaccine platforms and to define mechanistic correlates of protection.

Important nonlinear links between infection, inflammation, and disease severity were revealed using experimentally validated mathematical models.

In the absence of COVID-19 mitigation measures, SARS-CoV-2 remains infectious for longer than previously estimated.

Variation in SARS-CoV-2 viral kinetics are partly explained by an individual's immune state and the infecting variant, but substantial interpersonal variation limits the reliability of isolation policies tailored to an individual's vaccination status.

By distributing receptor-binding and receptor-destroying proteins asymmetrically on their surface, filamentous influenza A virus particles create a Brownian ratchet that facilitates their passage through mucus.

Interferon lambda 4, a protein part of the innate immune response, drives major amino acids selection in patients chronically infected with hepatitis C virus.

Very frequent viral kinetics in liver transplant patients reveals that the liver is not only the source of hepatitis C virus (HCV) production, but also plays a major role in extracellular HCV clearance.

Favipiravir, a novel nucleoside analogue, can clear a persistent norovirus infection in vivo through lethal mutagenesis.

COVID-19 severity, rather than sex or age, predicts SARS-CoV-2 kinetics, and SARS-CoV-2 viral load from lower respiratory tract specimens may predict severe disease days before clinical deterioration for COVID-19 patients.